Targeting RAF dimers in RAS mutant tumors: From biology to clinic

RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success in recent years, but there is still a lack of efficient therapeutic approaches for tumors with non-G12C KRAS mutations. A...

Cijeli opis

Bibliografski detalji

Glavni autori:	Huanhuan Yin, Qiulin Tang, Hongwei Xia, Feng Bi
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-05-01
Serija:	Acta Pharmaceutica Sinica B
Teme:	RAS mutations RAF dimerization RAF inhibitors Cancer therapy Drug resistance
Online pristup:	http://www.sciencedirect.com/science/article/pii/S221138352400056X
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!